首页> 外国专利> RECOMBINANT BCG EXPRESSING HIV-1 P24 USING PMYONG2 VECTOR SYSTEM AND USE THEREOF AS HIV-1 VACCINE

RECOMBINANT BCG EXPRESSING HIV-1 P24 USING PMYONG2 VECTOR SYSTEM AND USE THEREOF AS HIV-1 VACCINE

机译:使用PMYONG2载体系统表达HIV-1P24的重组BCG,并用途作为HIV-1疫苗

摘要

Provided is a recombinant BCG employing a pMyong2 vector system to express HIV-1 p24 and a use thereof as a HIV-1 vaccine. rBCG-pMyong2-p24, which is a pMyong2 vector system, was found to induce the upregulation of HIV-1 p24 gag expression in rBCG and infected antigen-presenting cells (APC) and to induce improved p24-specific immune responses in vaccinated mice, compared to rBCG-pAL-p24 in a pAL5000 derived vector system. rBCG-pMyong2-p24 was identified to exhibit a higher p24-specific Ab production level than rSmeg-pMyong2-p24 in the same pMyong2 vector system. Therefore, the recombinant BCG employing rBCG-pMyong2-p24 to express HIV-1 p24 according to the present invention is identified to elicit enhanced immune responses to HIV-1 infection in mouse model systems and thus can be expected to be used as a prime vaccine in the heterologous prime-boost vaccination strategy against HIV-1 infection.
机译:提供了一种具有PMYONG2载体系统的重组BCG,以表达HIV-1P24和其用途作为HIV-1疫苗。 RBCG-PMYONG2-P24,其是PMYONG2载体系统,发现在RBCG和感染的抗原呈递细胞(APC)中诱导HIV-1P24 GAG表达的上调,并在接种疫苗的小鼠中诱导改善的P24特异性免疫应答,与PAL5000衍生矢量系统中的RBCG-PAL-P24相比。鉴定RBCG-PMYONG2-P24在同一PMYONG2载体系统中表现出比RSMEG-PMYONG2-P24更高的P24特异性AB生产水平。因此,鉴定使用RBCG-PMYONG2-P24的重组BCG用于表达根据本发明的HIV-1P24,以引发小鼠模型系统中HIV-1感染的增强的免疫应答,因此可以预期用作主要疫苗在异源素促进疫苗接种策略中,抗HIV-1感染。

著录项

相似文献

  • 专利
  • 外文文献
  • 中文文献
获取专利

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号